Search the Newsreel

Indaptus Therapeutics (INDP) slashes R&D costs and bolsters cash after $12M raise

Indaptus Therapeutics (INDP) significantly reduced its operating expenses and net loss in Q2 2026, bolstering its cash reserves with a $12 million private placement. The company reported an 83% drop in R&D costs and a narrowed net loss of $1.8 million, while it evaluates …

Indaptus Therapeutics (Nasdaq: INDP) cuts losses and raises $12M in Q2

Indaptus Therapeutics (INDP) significantly reduced its net loss in Q2 2026 to $1.8 million from $5.2 million in the previous year, primarily due to an 83% cut in R&D and a 37% decline in G&A expenses as it halted its Decoy20 clinical program and …

Hindprakash Industries Q1 Results: Net profit rises 780% YoY

Indaptus Therapeutics Inc (INDP) Earnings Forecast: Future EPS & Revenue Growth Estimates

Indaptus Therapeutics (INDP) to Announce Earnings on Monday

Indaptus Therapeutics (INDP) is set to release its Q2 2026 earnings before the market opens on Monday, August 17th, with analysts forecasting a loss of $1.57 per share. The company's earnings call is scheduled for Friday, August 21, 2026, at 9:30 AM ET. Previously, …

Indaptus Therapeutics Inc (INDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Indaptus Therapeutics Inc (INDP), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. The stock is currently trading between a resistance level of 2.63 and a support level of 0.82, …

Indaptus Therapeutics Inc (INDP) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Indaptus Therapeutics Inc (INDP), noting its current valuation score is 6.27, ranking 316 out of 385 in its industry. The company's P/E ratio is -0.10, which is significantly below its recent high and above its recent low. …

INDP|Indaptus Therapeutics Inc|Price:2.100|Chg%:+0.060

This article provides a comprehensive stock analysis of Indaptus Therapeutics Inc (INDP) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry, despite recent weak stock market performance. The analysis also covers institutional …

Indaptus Therapeutics Inc (INDP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Indaptus Therapeutics Inc (INDP), noting that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company. It highlights the company's current stock price, market capitalization, and a significant daily percentage …

Indaptus Therapeutics Market Sentiment

The article provides a market sentiment analysis for Indaptus Therapeutics (INDP), highlighting analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with an average price target significantly above the current stock price. Recent insider activity shows notable investments and …

Indaptus Therapeutics Inc (INDP) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividend payouts and stock splits for Indaptus Therapeutics Inc (INDP). It notes that the company has not distributed any dividends in the past five years. The article details several stock merger events with varying ratios, primarily from …

Indaptus Therapeutics Inc (INDP) Institutional Confidence

This article from TradingKey provides an overview of institutional confidence in Indaptus Therapeutics Inc (INDP). It lists key shareholders and their activity, including changes in shares held. The data focuses on individual and institutional shareholding as of July 24, 2026.

TradingKey

This page from TradingKey provides a detailed quarterly and annual income statement for Indaptus Therapeutics Inc (INDP). It includes comprehensive financial data stretching back several years, covering total revenue, operating expenses, R&D expenses, operating profit, and net income. The page also offers FAQs on …

Indaptus Therapeutics (INDP) Q3 2025 earnings summary

Indaptus Therapeutics (INDP) reported a Q3 2025 net loss of $3.0 million, with its lead candidate, Decoy20, in Phase 1 clinical trials for advanced solid tumors. The company completed the safety lead-in cohort for a combination study, showing tolerable safety and early stable disease …

Signal Proxy Intelligence Recommends Full Support for All Three Items at Indaptus Therapeutics, Inc. Annual Meeting

Signal Proxy Intelligence has published its recommendations for the Indaptus Therapeutics, Inc. annual meeting on August 10, 2026, advising full support for all three ballot items. The firm recommends "FOR" on the advisory vote on executive compensation, "FOR" on the election of directors, and …

Indaptus Therapeutics (INDP) Proxy filing Summary

Indaptus Therapeutics (INDP) has scheduled its Annual Meeting for August 10, 2026, to be held virtually. Key proposals include the election of Class II directors, ratification of Haskell & White LLP as independent auditor, and approval of a new equity incentive plan, all recommended …

Indaptus Therapeutics (NASDAQ: INDP) seeks approval for 2026 equity plan

Indaptus Therapeutics (NASDAQ: INDP) is seeking shareholder approval for its 2026 Equity Incentive Plan at the upcoming annual meeting on August 10, 2026. The plan will initially reserve 13,324,232 shares and includes an annual automatic increase of 5% of outstanding shares from 2027 through …

HPIL FY26 net loss widens to ₹1122.01 lakh

Hindprakash Industries Q4 Results 2026: Date, Revenue, PAT And Analyst Outlook